The stock market was quick to praise Malvern’s Endo International over its choice of new CEO and president on Friday, with the stock gaining 15.45 percent to $23.39 on the news, writes Linda Loyd for Philly.com. 

The board selected Paul V. Campanelli, the former CEO of Par Pharmaceutical which Endo purchased last year, as its new leader. He moves from his position as president of the company’s OTC drugs business which has generated around 60 percent of Endo’s revenue this year.

“The board is very confident that Paul is the right choice to lead Endo moving forward as we focus on operational execution, increasing the value of our attractive U.S. branded, U.S. generic, and international pharmaceutical assets,” said Roger Kimmel, Endo’s Chairman.

Read more about Campanelli at Philly.com here, and check out previous VISTA Today coverage of Endo here.